Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

14.41
+0.32502.31%
Volume:1.95M
Turnover:28.00M
Market Cap:1.28B
PE:-5.19
High:14.51
Open:14.06
Low:13.88
Close:14.09
Loading ...

TD Cowen Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
08 May

CFO Christopher R. Cline Reports Disposal of Common Shares in Travere Therapeutics Inc

Reuters
·
06 May

Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report

Simply Wall St.
·
04 May

Piper Sandler Sticks to Their Hold Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
02 May

Travere Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
02 May

Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates

Zacks
·
02 May

Earnings Flash (TVTX) Travere Therapeutics Q1 Adjusted Loss Per Share $0.19 vs. FactSet Est Loss $0.36

MT Newswires Live
·
02 May

BRIEF-Travere Therapeutics Q1 EPS USD -0.47 Vs. IBES Estimate USD -0.54

Reuters
·
02 May

Travere Therapeutics Q1 EPS USD -0.47 VS. Ibes Estimate USD -0.54

THOMSON REUTERS
·
02 May

Press Release: Travere Therapeutics Reports First Quarter 2025 Financial Results

Dow Jones
·
02 May

Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy

MT Newswires Live
·
29 Apr

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of Filspari® (Sparsentan) for Iga Nephropathy

THOMSON REUTERS
·
29 Apr

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

Business Wire
·
29 Apr

Travere, CSL Vifor announce EC approval of Filspari marketing authorization

TIPRANKS
·
29 Apr

BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy

Reuters
·
29 Apr

CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy

THOMSON REUTERS
·
29 Apr

Press Release: Travere Therapeutics to Report First Quarter 2025 Financial Results

Dow Jones
·
25 Apr

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
24 Apr

Travere Therapeutics Price Target Maintained With a $47.00/Share by Guggenheim

Dow Jones
·
14 Apr

Travere Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
10 Apr